Primary Central Nervous System Lymphoma

Sarah Löw; Tracy T. Batchelor

doi:10.1055/s-0038-1627470

Seminars in Neurology, Table of Contents

Semin Neurol 2018; 38(01): 086-094
DOI: 10.1055/s-0038-1627470

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Primary Central Nervous System Lymphoma

Sarah Löw

¹Neurology Clinic and National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany

,

Tracy T. Batchelor

²Division of Hematology/Oncology, Department of Neurology and Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts

› Author Affiliations

Abstract

Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma limited to the brain, spinal cord, leptomeninges, and eyes. The majority of patients are immunocompetent, with a median age of 65 years at diagnosis. Historically, whole-brain radiation therapy (WBRT) was the first and sole treatment for PCNSL. Today, due to the recognized neurotoxicity of WBRT, this modality is usually avoided in the treatment. Most chemotherapy regimens are based on high-dose methotrexate plus the anti-CD20 monoclonal antibody rituximab, leading to high response rates, but 5-year survival is still poor at approximately 30% compared with other extranodal lymphomas. New treatment strategies including high-dose chemotherapy/autologous stem cell transplantation, targeted therapies focusing on, for example, genetic alterations in B cells or mammalian target of rapamycin signaling, and immunotherapy with inhibitors of the programmed cell death 1 receptor are only a few options to improve the armamentarium against PCNSL.

Keywords

primary central nervous system lymphoma - whole-brain radiation therapy - autologous stem cell transplantation - methotrexate - rituximab

Full Text

References

References
1 Ostrom QT, Gittleman H, Fulop J. , et al. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17 (Suppl. 04) iv1-iv62
2 Batchelor TT, DeAngelis LM. Lymphoma and Leukemia of the Nervous System. New York, NY: Springer; 2013
3 Swerdlow SH, Campo E, Harris NL. , et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008
4 Braggio E, Van Wier S, Ojha J. , et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res 2015; 21 (17) 3986-3994
5 Chapuy B, Roemer MG, Stewart C. , et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 2016; 127 (07) 869-881
6 Abrey LE, Batchelor TT, Ferreri AJ. , et al; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23 (22) 5034-5043
7 Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 2011; 32 (06) 984-992
8 Zacharia TT, Law M, Naidich TP, Leeds NE. Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging 2008; 18 (04) 411-417
9 Chan CC, Rubenstein JL, Coupland SE. , et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011; 16 (11) 1589-1599
10 Fischer L, Jahnke K, Martus P, Weller M, Thiel E, Korfel A. The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. Haematologica 2006; 91 (03) 429-430
11 Bromberg JE, Breems DA, Kraan J. , et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 2007; 68 (20) 1674-1679
12 Binnahil M, Au K, Lu JQ, Wheatley BM, Sankar T. The influence of corticosteroids on diagnostic accuracy of biopsy for primary central nervous system lymphoma. Can J Neurol Sci 2016; 43 (05) 721-725
13 Abrey LE, Ben-Porat L, Panageas KS. , et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24 (36) 5711-5715
14 Ferreri AJ, Blay JY, Reni M. , et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21 (02) 266-272
15 Jang JE, Kim YR, Kim SJ. , et al. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. Eur J Cancer 2016; 57: 127-135
16 Herrlinger U, Schäfer N, Fimmers R. , et al. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol 2017
17 Correa DD, Maron L, Harder H. , et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007; 18 (07) 1145-1151
18 Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004; 62 (03) 451-456
19 Monje ML, Vogel H, Masek M, Ligon KL, Fisher PG, Palmer TD. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol 2007; 62 (05) 515-520
20 Mathew BS, Carson KA, Grossman SA. Initial response to glucocorticoids. Cancer 2006; 106 (02) 383-387
21 Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol 2005; 31 (01) 100-105
22 Nelson DF, Martz KL, Bonner H. , et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23 (01) 9-17
23 Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 2007; 69 (11) 1178-1182
24 DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. ; Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20 (24) 4643-4648
25 Glantz MJ, Cole BF, Recht L. , et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol 1998; 16 (04) 1561-1567
26 Ferreri AJ, Guerra E, Regazzi M. , et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004; 90 (02) 353-358
27 Ferreri AJ, Reni M, Foppoli M. , et al; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374 (9700): 1512-1520
28 Morris PG, Correa DD, Yahalom J. , et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 2013; 31 (31) 3971-3979
29 Doolittle ND, Korfel A, Lubow MA. , et al. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 2013; 81 (01) 84-92
30 Rubenstein JL, Hsi ED, Johnson JL. , et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013; 31 (25) 3061-3068
31 Batchelor T, Carson K, O'Neill A. , et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003; 21 (06) 1044-1049
32 Ferreri AJ, Cwynarski K, Pulczynski E. , et al; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016; 3 (05) e217-e227
33 Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H. , et al; European Organization for Research and Treatment of Cancer Lymphoma Group. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21 (24) 4483-4488
34 Sierra Del Rio M, Ricard D, Houillier C. , et al. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. J Neurooncol 2012; 106 (01) 143-146
35 Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol 2002; 58 (02) 175-178
36 Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 2011; 76 (10) 929-930
37 Holdhoff M, Ambady P, Abdelaziz A. , et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 2014; 83 (03) 235-239
38 Strowd III RE, Abuali IA, Grossman SA. Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma. CNS Oncol 2015; 4 (03) 131-135
39 Qian L, Zhou C, Shen J, Cen J, Yin W. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy. Oncotarget 2016; 7 (18) 25783-25790
40 Thiel E, Korfel A, Martus P. , et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11 (11) 1036-1047
41 Illerhaus G, Fritsch K, Egerer G. , et al. Sequential high dose immuno-chemotherapy followed by autologous peripheral blood stem cell transplantation for patients with untreated primary central nervous system lymphoma - a multicentre study by the Collaborative PCNSL Study Group Freiburg. Blood 2012;120(21): Abstract 302
42 Zhu JJ, Gerstner ER, Engler DA. , et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009; 11 (02) 211-215
43 Kasenda B, Ferreri AJ, Marturano E. , et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol 2015; 26 (07) 1305-1313
44 Fritsch K, Kasenda B, Schorb E. , et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia 2017; 31 (04) 846-852
45 Omuro A, Chinot O, Taillandier L. , et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2015; 2 (06) e251-e259
46 Langner-Lemercier S, Houillier C, Soussain C. , et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol 2016; 18 (09) 1297-1303
47 Wang N, Gill C, Betensky RA, Batchelor TT. Relapse patterns in primary CNS diffuse large B-cell lymphoma. Neurology 2015; 84 (14) 3-147
48 Plotkin SR, Betensky RA, Hochberg FH. , et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10 (17) 5643-5646
49 Soussain C, Hoang-Xuan K, Taillandier L. , et al; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 2008; 26 (15) 2512-2518
50 Kasenda B, Schorb E, Fritsch K, Hader C, Finke J, Illerhaus G. Primary CNS lymphoma--radiation-free salvage therapy by second autologous stem cell transplantation. Biol Blood Marrow Transplant 2011; 17 (02) 281-283
51 Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005; 23 (07) 1507-1513
52 Sun Y, Wang Y, Han S. , et al. Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study. Onco Targets Ther 2017; 10: 2595-2600
53 Raizer JJ, Rademaker A, Evens AM. , et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer 2012; 118 (15) 3743-3748
54 Han S, Wang M, Liu B, Yu J. Pemetrexed for primary central nervous system lymphoma in the elderly. Clin Transl Oncol 2016; 18 (02) 138-143
55 Zhao HT, Chen J, Shi SB, Tian J, Tao RJ. Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma. Med Oncol 2015; 32 (01) 351
56 Houillier C, Choquet S, Touitou V. , et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology 2015; 84 (03) 325-326
57 Rubenstein JL, Formaker P, Wang X. Lenalidomide is highly active in recurrent CNS lymphomas: phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide as maintenance monotherapy. Hematol Oncol 2015; 33: 175 . Abstract 137
58 Ghesquieres H, Houillier C, Chinot O. , et al. Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a “proof of concept” phase 2 study of the French LOC Network. Abstract 785 presented at the 58th Annual Meeting American Society of Hematology. 2016
59 Wilson WH, Young RM, Schmitz R. , et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015; 21 (08) 922-926
60 Dunleavy K, Lai C, Roschewski M. , et al. Phase I/II study of TEDDI-R with Ibrutinib in untreated and relapsed/refractory primary CNS lymphoma. Hematol Oncol 2015; 33: 174-175 . Abstract 136
61 Lionakis MS, Dunleavy K, Roschewski M. , et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 2017; 31 (06) 833-843.e5
62 Chamoun K, Choquet S, Boyle E. , et al. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: a retrospective case series. Neurology 2017; 88 (01) 101-102
63 Grommes C, Gavrilovic IT, Kaley T. , et al. Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). J Clin Oncol 2017; 35 (15) 7515 . DOI: 10.1200/JCO.2017.35.15_suppl.7515
64 Nayak L, Iwamoto FM, LaCasce A. , et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 2017; 129 (23) 3071-3073
65 Korfel A, Schlegel U, Herrlinger U. , et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol 2016; 34 (15) 1757-1763